View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 28, 2020updated 13 Feb 2020 10:32am

Coronavirus: Chinese scientists to test 30 therapeutic candidates

Researchers in China have chosen to test 30 existing medicines, biologically active natural products and the country’s traditional medicines for potential therapeutic effects against the Wuhan coronavirus (2019-nCoV), according to the Chinese Academy of Sciences (CAS).


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Researchers in China have chosen to test 30 existing medicines, biologically active natural products and the country’s traditional medicines for potential therapeutic effects against the Wuhan coronavirus (2019-nCoV), according to the Chinese Academy of Sciences (CAS).

The death toll due to the coronavirus infection has reached 106, while 4,515 people have been affected.

A team of researchers from CAS’ Shanghai Institute of Materia Medica and ShanghaiTech University are working to identify drugs for the SARS-like virus, reported Xinhua.

Coronavirus drug development in China

Led by Rao Zihe and Yang Haitao, researchers at ShanghaiTech University detailed a high-resolution crystal structure of the viral main proteinase (Mpro) of 2019-nCoV.

Mpro regulates the activities of virus replication complex and is considered a beneficial drug target.

Based on findings from this Mpro study, the joint team analysed marketed drugs and databases for compounds with high potency and those from medicinal plants. Researchers used virtual screenings and enzymology tests to select 30 potential therapeutic candidates.

In addition to 12 HIV medicines, including Saquinavir, Indinavir, Lopinavir, ritonavir and Carfilzomib, the selected candidates comprise two respiratory syncytial virus drugs, a schizophrenia medication and an immunosuppressant.

Candidates also include certain traditional Chinese medicines that may consist of components with efficacy against the Wuhan coronavirus, such as Polygonum cuspidatum.

The team claim that these drug candidates can be considered for clinical treatment of pneumonia in patients infected with the virus.

CAS adds that the candidates will be tested to offer guidance for clinical studies and treatments.

Coronavirus drug development internationally

Many companies and research organisations are in a race to develop preventives and treatments for the coronavirus infection. The US National Institutes of Health (NIH) is among the first to commence works for the development of a vaccine.

Inovio Pharmaceuticals and Moderna secured CEPI funding to develop vaccines, while Gilead Sciences is testing the potential use of its investigational Ebola drug to treat the coronavirus.

The CEPI also contacted the University of Queensland in Australia for the development of a vaccine.

Moreover, GeoVax Labs partnered with a vaccine company called BravoVax in Wuhan, China to co-develop a coronavirus vaccine candidate.

GeoVax will leverage its MVA-VLP vaccine platform to design and create the vaccine, while BravoVax will be responsible for further development.

BravoVax will provide testing and manufacturing support, as well as enable direct discussions with public health and regulatory authorities in China.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology